Organizing Committee
OCM Member
Research Director
French National Institute of Health and Medical Research , France
Biography :

Dr. Camille Locht holds currently a position as Research Director at the French National Institute of Health and Medical Research (Inserm) and, since 2010, is the founding director of the Center for Infection and Immunity of Lille on the campus of the Institut Pasteur de Lille in France. He has obtained his PhD at the Catholic University of Leuven in Belgium in 1984. After a 3-years post-doctoral stay at the National Institute of Allergy and Infectious Disease in the USA, where he started to work on pertussis and cloned the pertussis toxin genes, he joined SmithKline – Beecham (now GSK) to help developing acellular pertussis vaccines. Since 1989 he is the head of a research laboratory at the Institut Pasteur de Lille, where he has been the Scientific Director from 2002 to 2013. His research interest is in molecular pathogenesis of respiratory infections, essentially pertussis and tuberculosis, with the long-term aim to develop new tools to combat these diseases. A very powerful molecular typing system for mycobacteria, invented in his laboratory has already reached the market, and a live attenuated nasal pertussis vaccine developed in his laboratory has now successfully completed phase I clinical trials and is currently in clinical development. He also has discovered a protective mycobacterial latency antigen, called heparin-binding haemagglutinin (HBHA), which is now in late stage pre-clinical development as an anti-tuberculosis vaccine candidate. He has authored more than 300 international publications, book chapters and patents and has obtained several research awards.

OCM Member
CTO
AFFiRiS AG , Austria
Biography :

Günther Staffler is Chief Technology Officer (CTO) and Member of the Executive Board of AFFiRiS. Prior to his appointment to the Executive Board Günther led the Immunology Department. Günther Staffler completed his degree in biochemistry and immunology at the Institute for Immunology of University of Vienna. He has also been a lecturer at the University of Vienna (1997-2001). After a postdoctoral stay at InterCell AG between 2001 and 2003 Dr. Staffler joined the biotech company Biovertis AG where he was first responsible in establishing the program for identification of essential genes in different pathogenic organisms. Besides setting up the microbiology department he became also responsible for the preclinical development at Biovertis AG. During his research career Dr. Staffler has authored many publications in international journals and was awarded the “Förderungspreis” of the Austrian Society of Chemistry in 1996 and the “Ursula und Fritz Melcher’s Preis” of the Austrian Society of Immunology in 2003.

OCM Member
CSO and Managing Director
OncoQR ML GmbH , Austria
Biography :

Dr. Geert C. Mudde received a Ph.D. in immunology from the University of Utrecht in 1985 and started his international professional career at the Swiss Institute for Asthma and Allergy Research in Davos in 1989. In 1992 he joined the pharmaceutical/biotech industry, where he held several senior management positions at the Novartis Research Institute in Vienna, Austria, the Parke Davis Research Institute in Fresnes, France, Ingenium Pharmaceuticals, Martinsried, Germany, and at igeneon AG, Vienna, Austria. Finally, in 2006, while joining Baxter BioScience in Vienna as interim manager, Dr. Mudde co-founded the biotech company f-star Biotechnology, where he served as “Chief Scientific Officer” from 2007 to 2009. In 2009, together with Christof Langer, he started to develop the S-TIR™ technology platform for human specific therapeutic vaccines which led to the foundation of S-TARget therapeutics GmbH in 2010. Since then he serves as CSO and managing director for S-TARget therapeutics as well as for the S-TIR™ technology spin-off companies OncoQR ML GmbH and TYG oncology Ltd., which were both founded in 2013

Research Interest :

Immunology, S-TIR™ technology platform for human specific therapeutic vaccines

OCM Member
CEO, MRGN Advisors – Chairman
Virometix , Switzerland
Biography :

Pierre A. MORGON is Chief Executive Officer of MRGN Advisors, a consultancy dedicated to the healthcare sector, and Regional Partner for Switzerland at Mérieux Développement, an evergreen investment structure focused on medical devices, in vitro diagnostics and patient management services. Chairman of the Board of Virometix, a company developing proprietary synthetic nanoparticle platform in vaccines and immunotherapeutic drugs for viral diseases and cancer. He holds a Doctorate of Pharmacy, a Master in Business Law and a MBA. He is also an alumnus of INSEAD, IMD and MCE executive programs. Board positions: Non-Executive Director to the Board of Theradiag, a company focusing on in vitro diagnostics in auto-immunity, infectious diseases and allergy. Non-Executive Director to the Board of Eurocine Vaccines, a company dedicated to developing intra nasal vaccines.

OCM Member
UC Davis School of Veterinary Medicine , USA
Biography :

Tilahun Yilma is a Distinguished Professor of Virology at UC Davis. He is noted for developing what the journal Nature described as one of the two outstanding vaccinia virus recombinant vaccines in the world. He is also noted for developing a method for enhancing the safety and efficacy of recombinant vaccines with the use of cytokines as attenuating and adjuvant genes. Yilma has received many national and international awards for his research contributions. He is also a member of the US National Academy of Sciences and a Fellow of the American Academy of Microbiology.

OCM Member
Professor, Centre for Infection and Immunity
Queen's University Belfast , United Kingdom
Biography :

Professor S. Louise Cosby (SLC) was appointed as Head of Virology Branch at the Agri-Food and Biosciences institute, UK, in 2015. She was Chair of Microbiology in Queen’s University Belfast from 2002 and remains an emeritus professor. SLC is a Fellow of Royal College of Pathologists (London) and Fellow of the Royal Society of Biology, UK. She has served/currently serves on grant/editorial boards: BBSRC, UK; Chair/member, Science Foundation Ireland; Deputy Chair Professional Development Committee, Microbiology Society, UK; Associate Editor, Journal of Neurovirology, USA; Review editor, Frontiers in Microbiology; External Assessor for Appointments and Promotions in Medical Microbiology, University of Malaysia. Research interests: in virus pathogenesis including virus-receptor interactions, virus-induced immunosuppression as well as novel diagnostics and vaccine development. Work has focused on paramyxoviruses of both human and veterinary interest, with publications/grant funding in this area.

OCM Member
Professor of Vaccinology, Department of Medicine
University of Oxford , United Kingdom
Biography :

Prof Martin Bachmann established that epitope repetitiveness is a geometric pathogen-associated molecular pattern (PAMP). He demonstrated that highly repetitive structures enhance B cell responses by efficiently cross-linking B cell receptors as well as effectively recruiting the innate humoral immune system. This offers an explanation for the high immunogenicity of viruses and many bacteria. He has harnessed the concept of epitope repetitiveness as a molecular PAMP to develop a new vaccine platform. The basis of the vaccines are epitopes chemically conjugated to virus-like particles. Preclinical proof-of-concept (PoC) has been reached with numerous prophylactic and therapeutic vaccines. Using this technology, pioneering clinical PoC has been obtained for vaccines for the treatment of hypertension and smoking. Based on this technology, Novartis has a program for Alzheimer’s disease ongoing and Pfizer has a program in the field of allergy. A*Star in Singapore conducted a clinical study for a vaccine against influenza virus in 2013. He established that toll-like receptor 9 ligands packaged into VLPs are more potent than free toll-like receptor 9 ligands and at the same time exhibit better tolerability. Based on these insights he initiated numerous clinical trials, resulting in encouraging data for a vaccine against melanoma and clinical PoC for the treatment of allergy and asthma. He has developed a number of novel technologies, including new expression systems, a functional genomics technology based on mammalian cell display and a technology to isolate fully human antibodies.

Research Interest :

Immunology, S-TIR™ technology platform for human specific therapeutic vaccines

OCM Member
Chair, Division of Immunology
Utrecht University , Netherlands
Biography :

Willem van Eden (MD, PhD) is professor of Immunology in the Veterinary Faculty of Utrecht University and Head of the division of Immunology. Aner his MD training (Groningen), he obtained his PhD in the area of immunogene3cs at Leiden University (1983) and spent several years for postdoctoral training at the Weizmann Ins3tute (Israel), where he developed models of experimental autoimmunity. In 1985 he obtained a posi3on at the veterinary faculty in Utrecht. From 1986-1989 he received specialty training in Medical Microbiology in Utrecht University Medical Centre. He was member of Health Council of the Netherlands (Gezondheidsraad), advising the minister with respect to the na3onal vaccina3on program and he is member of the ECDC Scien3fic Advisory Panel on Vaccines and Immuniza3on (EVAG, ECDC Stockholm). He is in the Scien3fic advisory board of Mucosis BV (mucosal vaccina3on) and the Biomedical Primate Centre (BPRC) in Rijswijk. He was coordinator of 4 EU research programs (FP4-6) in the area of vaccines, infec3ous diseases and chronic inflamma3on. He is founder and CSO of Trajectum Pharma BV (immuno-modulatory vaccines for autoimmune diseases). He is chief editor of Fron3ers in Nutri3onal Immunology and receiving Editor for Cell Stress & Chaperones (Springer Verlag) and FEMS Pathogens and Disease (Oxford University Press). His key areas of interest are immuno-regula3on and immunomodula3on through stress proteins and autoimmunity. He has pioneered the area of stress proteins (heat shock proteins) and their use for immuno-regulatory (pep3de) vaccines.

Research Interest :

Immunology, S-TIR™ technology platform for human specific therapeutic vaccines

OCM Member
Professor
American University of Beirut , Lebanon
Biography :

Prof. Salim Adib is a medically-trained epidemiologist, who obtained a Doctorate of Public Health (DrPH) in 1991 at the University of Michigan (Ann-Arbor, USA). He has been involved in various academic activities, research, community service and public consultations in the USA (1986-93) and Kuwait (1995-2002). Between 2010 and 2012, he was the Manager of the Public Health Department of the Emirate of Abu-Dhabi (UAE). In 2013, he served as a Professional International Expert for the NCD Department at the WHO-East Mediterranean Regional Office in Cairo. Prof. Adib is an adjunct professor at the UAE University in Al-Ain (since 2010). Since 2014, he has been affiliated as senior lecturer with the Department of Epidemiology and Population Studies at the American University in Beirut. He is a frequent consultant to the Lebanese Ministry of Public Health. He was elected IEA Council Member for the Middle-East and North Africa region in 2014. Dr. Adib also serves as Chair of the Examination Committee of the Arab Board for Family and Community Medicine.

Research Interest :

Immunology, S-TIR™ technology platform for human specific therapeutic vaccines

OCM Member
University of Grenoble-Alpes , France
Research Interest :

Vaccines against Human Herpesviruses and Research interest on Hepatitis C Virus

OCM Member
President
Foundation de Beaumont Bonelli for cancer research , Italy
Biography :

Giulio Tarro graduated from Medicine School, Naples University (1962). Research Associate, Division of Virology and Cancer Research, Children’s Hospital (1965-1968), Assistant Professor of Research Pediatrics, College Medicine (1968-1969), Cincinnati University, Ohio. Oncological Virology Professor, Naples University (1972-1985). Chief Division Virology (1973-2003), Head Department Diagnostic Laboratories, (2003-2006). D. Cotugno Hospital for Infectious Diseases, Naples; Emeritus, 2006 -. Since 2007 Chairman Committee of Biotechnologies and VirusSphere, World Academy Biomedical Technologies, UNESCO, Adjunct Professor Department Biology, Temple University, College of Science and Technology, Philadelphia, recipient of the Sbarro Health Research Organization lifetime achievement award (2010). His researches have been concerned with the characterization of specific virus-induced tumour antigens, which were the "finger-prints" left behind in human cancer. Achievements include patents in field; discovery of Respiratory Syncytial Virus in infant deaths in Naples and of tumor liberated protein as a tumor associated antigen, 55 kilodalton protein overexpressed in lung tumors and other epithelial adenocarcinomas.

Research Interest :

characterization of specific virus-induced tumour antigens, which were the "finger-prints" left behind in human cancer

Mail us at

Registration Query
vaccinesworld@alliedconferences.org
General Query
vaccinesworld@alliedmeetings.org
Abstract Submission
vaccinesworld@alliedconferences.org
More details about sponsorship:sponsors@alliedacademies.com
Copyright © 2017-2018 Allied Academies, All Rights Reserved.